A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-16 and is reviewed periodically as new material appears.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Analog of an ACTH fragment |
| Amino acid length | Seven residues | Met-Glu-His-Phe-Pro-Gly-Pro |
| Origin | Moscow, 1980s | Institute of Molecular Genetics |
| Approved regions | Russia and some neighboring states | Not cleared in Western markets |
| Common trade names | Multiple national brands | Sold as a nasal formulation |
Semax 是人工设计的七肽，序列为 Met-Glu-His-Phe-Pro-Gly-Pro，骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性，同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。
当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应，Semax 属于这一路线。鼻内给药是其主要使用方式，俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上，样本规模与终点设置同西方试验惯例存在差异，国际同行对其临床证据的强度看法不一。
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
The LAL test is a major source of animal product dependence in the biomedical industry, and a challenge to the Three Rs of science in relation to the use of animals in testing. With reports of higher-than anticipated mortality rates it has been considered more ethical to devise alternatives to the test. Since 2003, a recombinant protein substitute for use in the LAL test has been commercially available. Named the recombinant factor C (rFC) assay, it is based on the same Limulus clotting factor C protein, but produced by genetically modified insect cells (the specific factor C sequence used does not necessarily come from the Atlantic horseshoe crab). Instead of emulating the whole clotting pathway, rFC tests let factor C cleave a synthetic fluorogenic substrate, so that the sample lights up when endotoxin activates the factor. Since it does not contain factor G, (1,3)-β-D-glucan will not cause false-positives. As of 2018, available evidence shows that the rFC test is no worse than the LAL test. The adoption of the rFC test was slow, which began to change in 2012 when the US FDA and the European health ministry acknowledged it as an accepted alternative. Its lack of mention in Pharmacopeias remained an issue, as there was no good standard for running the test in production. In 2016, it was added to the European Pharmacopoeia. A patent on rFC also limited adoption until its expiration in 2018.
=== Alzheimer's disease === The "amyloid hypothesis" — that Aβ, either already in plaques, or as oligomers that may act outside of plaques, is responsible for the pathology of Alzheimer's disease — has been the dominant hypothesis for around thirty years as of 2025, but is not conclusively established, especially because over time it has become clear that there are many causes of Alzheimer's (outside of people who develop early-onset Alzheimer's disease which is clearly driven by Aβ), and because many people who have plaques never develop Alzheimer's. Scientists in the field have wondered if plaques may be a response to the disease process, rather than the cause of it. Research suggests that soluble oligomeric forms of the amyloid beta may be causative agents in the development of Alzheimer's disease. It is generally believed that Aβ oligomers are the most toxic. Several genetic, cell biology, biochemical and animal studies using experimental models support the concept that Aβ plays a central role in the development of Alzheimer's disease pathology. Brain Aβ is elevated in people with sporadic Alzheimer's disease. Aβ is the main constituent of brain parenchymal and vascular amyloid; it contributes to cerebrovascular lesions and is neurotoxic. It is unresolved how Aβ accumulates in the central nervous system and subsequently initiates the disease of cells.
== Life and work == Magati was born in Scandiano, Reggio Emilia, in the landed family of Giorgio and Laura Mattacoda. A brother, Giovanni Battista, became a physician while a sister became the grandmother of Antonio Vallisneri. He studied at Pauda and from 1596, medicine at the University of Bologna. Graduating in 1597 he worked at the Hospital of Santa Maria della Consolazione in Rome. He was influenced by the teachings of Flaminio Rota, Giulio Cesare Claudini, and Giovanni Battista Cortese. He then took the exam of the College of Physicians and became a surgeon at the Hospital of Santa Anna. He then returned to Scandiano and around 1612, through the influence of Marquis Enzio Bentivoglio, he became a lecturer in surgery at Ferrara. In 1618 he became very ill and gave up teaching. He joined the Capuchin order as a lay brother in 1618 and took his vows in Ravenna the next year, and going by the name of Padre Liberato da Scandiano. He continued to practice medicine for the House of Este. In 1647 Magati was operated on for gall-stones at Bologna but he died three days after the surgery. Magati's major contribution was in wound hygiene and healing. He went against the contemporary practice of frequent change in dressing and the use of ointments. He instead suggested that natural processed played a key role in healing and that these processes needed to be aided. For this he is remembered as a fundamental reformer of surgery.
Sources: en.wikipedia.org
Despite his clean energy policies and congressional Republicans characterizing them as a "War on American Energy", domestic oil production reached a record high in October 2023. Biden has said the U.S. needs to "get tough" on China, calling it the "most serious competitor" that poses challenges to the United States' "prosperity, security, and democratic values". Biden has spoken about human rights abuses in the Xinjiang region to Chinese leader Xi Jinping, pledging to sanction and commercially restrict Chinese government officials and entities who carry out repression. Biden has said he is against regime change but is for providing non-military support to opposition movements. He opposed direct U.S. intervention in Libya, voted against U.S. participation in the Gulf War, voted in favor of the Iraq War, and supports a two-state solution in the Israeli–Palestinian conflict. Biden pledged to end U.S. support for the Saudi Arabian-led intervention in Yemen and to reevaluate the United States' relationship with Saudi Arabia. Biden supported extending the New START arms control treaty with Russia to limit the number of nuclear weapons deployed by both sides. In 2021, Biden officially recognized the Armenian genocide, becoming the first U.S. president to do so. Biden supported abortion rights throughout his presidency, though he personally opposes abortion because of his Catholic faith. In 2019, he said he supported Roe v. Wade and repealing the Hyde Amendment. After Dobbs v.
== Treatment == Smallpox vaccination within three days of exposure will prevent or significantly lessen the severity of smallpox symptoms in the vast majority of people. Vaccination four to seven days after exposure can offer some protection from disease or may modify the severity of the disease. Other than vaccination, treatment of smallpox is primarily supportive, such as wound care and infection control, fluid therapy, and possible ventilator assistance. Flat and hemorrhagic types of smallpox are treated with the same therapies used to treat shock, such as fluid resuscitation. People with semi-confluent and confluent types of smallpox may have therapeutic issues similar to patients with extensive skin burns. Antiviral treatments have improved since the last large smallpox epidemics, and as of 2004, studies suggested that the antiviral drug cidofovir might be useful as a therapeutic agent. The drug must be administered intravenously, and may cause serious kidney toxicity. In July 2018, the Food and Drug Administration approved tecovirimat, the first drug approved for treatment of smallpox. However, during treatment viral mutations causing resistance have been known to occur, especially since its use in the 2022–2023 mpox outbreak which jeopardize its effectiveness for smallpox biothreat preparedness. In June 2021, Brincidofovir was approved for medical use in the United States for the treatment of human smallpox disease caused by variola virus.
According to US Chamber of Commerce 70% of all illicit drug users are employed. Some industries have high rates of employee drug use such as construction (12.8%), repair (11.1%), and hospitality (7.9-16.3%).
Sources: en.wikipedia.org
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.
It is registered as a medicine in Russia and has been used clinically there for decades. No regulatory agency in Western Europe or North America has approved it for any indication.
Semax corresponds to the four-to-ten fragment of adrenocorticotropic hormone. Because it omits the first three residues, it lacks the adrenal-stimulating action of the full hormone.
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.